Cabergoline

Cabergoline is a dopamine receptor agonist used for the treatment of hyperprolactinemic conditions due to various causes. Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor.

Chemical structure of Cabergoline
Mechanism
Curator reviewed
Primary indication
For the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas).Curator reviewed · 3 structured indications
Formula / weight
C26H37N5O2 · 451.6043 g/mol (avg)
First approval
Canada, 2003 · United States, 1996
Code names
FCE-21336
Brand names
  • Dostinex

Resolves to

Structure
InChIKeyKORNTPPJEAJQIU-KJXAQDMKSA-NSMILES[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC
Transporters

What you can answer from here — as of September 23, 2026

21Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1TransporterSubstrate / inhibitor direction, not just membership
Listed above
1,614Drug interactionsStructured to mechanism, not free text
Sign in
66Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
5ContraindicationsEach with its own population and attribute set
Sign in
367Marketed productsAcross 9 countries and 45 labellers
Sign in
2ATC codesIncluding every combination product, plus 34 drug categories
Sign in
72+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Cabergoline, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account